Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15:24 | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
NEUROSENSE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
10.09. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
10.09. | NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons | 94 | PR Newswire | Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile
CAMBRIDGE, Mass., Sept. 10... ► Artikel lesen | |
08.09. | RECIPHARM AB: Recipharm partners with NeuroSense Therapeutics to advance ALS therapy PrimeC toward Phase 3 trials | 2 | Cision News | ||
04.09. | NeuroSense Therapeutics announces $500,000 private placement | 1 | Seeking Alpha | ||
02.09. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
20.08. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
15.08. | NeuroSense Therapeutics Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
01.08. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
10.07. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
26.06. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
12.05. | This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday | 19 | Benzinga.com | ||
12.05. | Boral Capital starts NeuroSense stock with Buy, $14 target | 12 | Investing.com | ||
07.05. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
24.04. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
24.04. | NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update | 164 | PR Newswire | Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about... ► Artikel lesen | |
09.04. | NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment | 283 | PR Newswire | New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS.
CAMBRIDGE, Mass., April 9, 2025 /PRNewswire/... ► Artikel lesen | |
08.04. | NeuroSense Therapeutics GAAP EPS of -$0.54 | 3 | Seeking Alpha | ||
07.04. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
07.04. | NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates | 160 | PR Newswire | Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline
Ongoing partnership... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CARDIOL THERAPEUTICS | 0,930 | +0,65 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
12.08.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
CIDARA THERAPEUTICS | 73,50 | -2,65 % | Cidara Therapeutics: sharedealsPlus-Tipp mit +793% in 11 Monaten | Mit Cidara Therapeutics zaubert ein Dauerbrenner unserer sharedealsPlus-Community eine wahnsinnige Performance in die Depots: +793% innerhalb eines Jahres sprechen eine klare Sprache: Das Biotechunternehmen... ► Artikel lesen | |
QIAGEN | 37,645 | -2,03 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 50 Euro auf "Buy" belassen. Der Diagnostikspezialist liege mit seinen Innovationen im Bereich... ► Artikel lesen | |
EVOTEC | 6,038 | -3,05 % | Adidas schluckt Puma? Evotec mit Insiderkauf! 50 % Kurspotenzial mit KI-Aktie NetraMark! | Adidas und Puma im Fusionsfieber? Ein US-Investor bringt die spektakuläre Idee ins Spiel. Ist es ein Druckmittel gegenüber dem Puma-Management oder tatsächlich eine Option? Was sagen Analysten? Währenddessen... ► Artikel lesen | |
SCISPARC | 6,140 | +60,31 % | SciSparc stock soars after launching quantum computing initiative | ||
PEPGEN | 5,580 | +110,57 % | Morning Market Movers: PepGen, 22nd Century Group, Immuneering, Transocean See Big Swings | OTTAWA (dpa-AFX) - At 7:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
IMMUNEERING | 7,925 | -13,76 % | Mizuho bestätigt Outperform-Rating für Immuneering nach positiven Studiendaten | ||
EDGEWISE THERAPEUTICS | 14,880 | -10,31 % | Goldman Sachs initiates Edgewise Therapeutics stock with Neutral rating | ||
BIONTECH | 84,05 | -1,18 % | PAUKENSCHLÄGE bei Megatrend-Aktien: Rheinmetall, BioNTech, First Hydrogen | Rheinmetall gibt Vollgas: zu Land, zu Wasser, in der Luft und im Weltraum. Jüngster Paukenschlag ist die angekündigte Übernahme der Marinesparte von Lürssen. Ist das der Rückenwind für die Aktie, um... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,635 | -5,02 % | Looking for the Next Big Pop? Here's Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce | ||
MINERALYS THERAPEUTICS | 38,570 | -0,95 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
89BIO | 14,685 | -0,07 % | Roche kauft amerikanische 89bio für bis zu 3,5 Milliarden Dollar | BASEL (dpa-AFX) - Roche übernimmt für bis zu 3,5 Milliarden US-Dollar die amerikanische 89bio. Das Biopharma-Unternehmen leistet laut Roche Pionierarbeit bei der Entwicklung innovativer Therapien zur... ► Artikel lesen | |
MBX BIOSCIENCES | 17,250 | -15,11 % | MBX Biosciences, Inc.: MBX Biosciences Announces Pricing of Upsized Public Offering | CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide... ► Artikel lesen | |
EVAXION | 4,510 | +36,67 % | Evaxion Out-licenses Vaccine Candidate EVX-B3 To Merck & Co. | KENILWORTH (NJ) (dpa-AFX) - TechBio company Evaxion A/S (EVAX) announced Thursday it has out-licensed its vaccine candidate EVX-B3 to Merck & Co., Inc. or MSD (MRK), as per the option and license... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 40,960 | -5,25 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen |